Article Figures & Data
Figures
- Figure 1. Flowchart showing the process for identification of studies suitable for inclusion
Tables
Authors (Year) Country Setting Sample size (treatment/control) Mean age (SD) Inclusion criteria Treatment Primaryoutcome Findings Gautret et al (2020) France Hospitals in Marseille, Nice, Avignon and Briançon 6 – AZT and HCQ14 – HCQ alone16 – control Treatment groups: 51.2 (18.7)Control: 37.3 (24.0) SARS-CoV-2 carriage in nasopharyngeal sample
Age>12 years (treatment groups only)
Six patients received 500 mg AZT on Day 1 then 250 mg daily for four days and200 mg HCQ three times a day for 10 days.14 patients received 200 mg HCQ three times a day for 10 days. Outcome of a nasopharyngeal swab on Day 6 Virological cure:AZT and HCQ – 100%HCQ alone – 57.1%Controls – 12.5% p<0.001 AZT = azithromycin; HCQ = hydroxychloroquine.
Bias Rapid review authors’ judgment Reason for judgment Random sequence generation High risk Non-randomised trial Allocation concealment High risk Open-label Blinding High risk Open-label Incomplete outcome data High risk Intention-to-treat analysis not performed Selective reporting Unclear risk No adverse event data reported, although the authors state that this will be reported separately at the end of the trial Other bias High risk Under-powered according to the authors’ own power calculation
Supplementary Data
SUPPLEMENTARY MATERIALS
- bjgpopen20X101094_Supp.pdf -
Supplementary material is not copyedited or typeset, and is published as supplied by the author(s). The author(s) retain(s) responsibility for its accuracy.
In this issue
Should azithromycin be used to treat COVID-19? A rapid review
Jump to section
More in this TOC Section
Related Articles
Cited By...
Intended for Healthcare Professionals
